Loading Events

« All Events

  • This event has passed.

Learning from Black Entrepreneurs, Investors and Executives

January 18 @ 1:21 am

Diversity creates a strategic advantage. According to the BIO diversity report, people of color make up 32% of the biotech workforce. Yet, only 15% of executive teams and 14% of biotech company boards are inclusive of BIPOC (Black, Indigenous, People of Color). Representation matters!

 

On this panel, you will hear from top VC’s and Entrepreneurs of color. They will share their experiences working in life sciences, discuss the challenges they faced, and how the industry will benefit from being more inclusive.

SPEAKERS

MODERATOR: Michael Penn, MD, PhD, Founder and Managing Director, Health Equities Venture

Dr. Michael L. Penn, Jr. is founder and Managing Director of Health Equity Ventures–an emerging investment fund supporting companies leveraging technology and data to accelerate healthcare transformation for underserved populations. Dr. Penn also maintains a vigorous diversity and innovation consulting business and serves as an advisor to Culture Shift Labs where he co-leads their inclusive healthcare ecosystem.

Ibraheem Badejo, PhD – Sr Dir – New Ventures, Johnson & Johnson Innovation Center

Ibraheem (Ib) leverages his expertise in smart materials and biomaterials to support the medical device sector of Johnson & Johnson. From 2010 to 2013, Ib was a Research Fellow at Global Surgery Group of Johnson & Johnson, where he was responsible for external and front-end innovations and intellectual property for Ethicon Biosurgery. From 2006 to 2010, he was the Director of Applied Research & New Technology Assessment of novel biomaterials. Prior to that, he was the Chief Scientist of Closure Medical Corp (acquired by Johnson & Johnson in 2005). Ib has held various positions at Bayer, North Carolina State University, and the College of Charleston.

Roslyn Rawlins, Co-Founder and CEO, Bleuberi

Roslyn Rawlins is the Co-Founder and CEO of Bleuberi a secure mobile health platform and data collection portal that allows the patient community living with epilepsy to better manage their complex chronic health condition.Roslyn is known for her community service, and advocacy for social & racial justice, equity, and inclusion for disability, senior, underserved, and marginalized communities. Roslyn has served as the Board Chairperson of Epilepsy Education Everywhere, is a Community Board Member of The Brain Recovery Project, and serves as a Co-Admin for Parents of Children with Frontal Lobe Seizures and Parents of Children with Absence Seizures social media 10,000 memeber forum groups.

Uciane Scarlett, PhD, Principal, Oxford Science Innovations

Uciane joined OSI as a Principal in December 2019. At OSI, Uciane currently represents OSI on the boards of PepGen, Scenic, MiroBio, Dark Blue Therapeutics, and DJS and is exploring new opportunities in cell therapy and neurosciences. She is also working on a pre-seed initiative which will launch in 2021, Pulsa. She was previously an investor and EIR at the US-based fund, Atlas Venture, where she focused on company creation, early-stage investing, and operations within Atlas portfolio companies. Uciane holds a PhD in cancer immunology from Dartmouth College.

Nick Davis, ScD, Founding Partner & CEO, Epitoire

Nick Davis is an expert in industrialized drug discovery, systems biology and functional genomics, and brings a decade of hands-on experience discovering and scaling technologies across the biotech and pharma industries. With a passion for improving access to quality healthcare, Nick founded Epitoire Inc. in 2018 as the first drug discovery company focused on developing small-molecule medicines for tRNA pathobiology in complex, multigenic diseases. Nick currently serves as President & Chief Executive Officer of Epitoire, Inc. Nick is also Founder and acting-CEO of Traffic Therapeutics, Inc., a company he co-founded in 2019 to advance a new approach to precision oncology with third-generation antibody-drug conjugates (ADCs) and antibody-oligonucleotide conjugates (AOCs) that act on the immuno-oncology axis.

Details

Date:
January 18, 2022
Time:
1:21 am